ライフサイエンスコーパス: intussusception

1 t to be possibly vaccine-related (intestinal intussusception).

2 None of the infants had confirmed intussusception.

3 ds to assess the association between RV1 and intussusception.

4 increased the ability to diagnose or exclude intussusception.

5 as negative, positive, or indeterminate for intussusception.

6 ter studies showed a strong association with intussusception.

7 n and safe from the possible complication of intussusception.

8 thheld because of multiple reported cases of intussusception.

9 of a mouse model to study rotavirus-induced intussusception.

10 e risk of the association between RRV-TV and intussusception.

11 ation of the vaccine with the development of intussusception.

12 substantially greater than the rare risk of intussusception.

13 xplore here the effect of age on the risk of intussusception.

14 er cuff, the "pluck" technique, and ureteral intussusception.

15 s vaccine (OPV), may also be associated with intussusception.

16 tion between natural rotavirus infection and intussusception.

17 ism by which rotavirus infection could cause intussusception.

18 the rotavirus vaccine and the development of intussusception.

19 rtant benefits that outweigh risk related to intussusception.

20 ithdrawn after an association was found with intussusception.

21 en suspected of having abnormalities such as intussusception.

22 viruses has been found to be a rare cause of intussusception.

23 virus vaccine suggested an increased risk of intussusception.

24 born at the same hospital as the infant with intussusception.

25 of rotavirus vaccine (Rotashield) and infant intussusception.

26 here are 58 cases of surgically proven adult intussusception.

27 ignant colonic lesions associated with their intussusception.

28 pies, of which two also had small intestinal intussusception.

29 dered in the differential diagnosis of bowel intussusception.

30 contributes to less than 5% of all cases of intussusception.

31 at acted as a leading point to an ileo-ileal intussusception.

32 1 probable, 10 possible and 10 suspected for intussusception.

33 V5 and RV1 outweigh the small excess risk of intussusception.

34 was based on only 12 cases with both CD and intussusception.

35 There were 44 enteric and 14 colonic intussusceptions.

36 e small-bowel and 143 (71.5%) were ileocolic intussusceptions.

37 rentiation between ileocolic and small-bowel intussusceptions.

38 An increased risk of intussusception 1 to 7 days after the first dose of RV1

39 Seventy-four of the 429 infants with intussusception (17.2 percent) and 226 of the 1763 contr

40 ed prolonged urine leak (10), infection (6), intussusception (2), and transient renal insufficiency (

41 An increased risk of intussusception 3 to 14 days after the first dose of RRV

42 Intussusception, a condition in which the intestine acut

43 but on AIN76A diet also developed intestinal intussusception, a tumor-associated pathology in patient

44 , at most, a 7% increase in the incidence of intussusception above the annual background incidence.

45 The total intussusception admission risk attributable to Rotashiel

46 We found no evidence of increased infant intussusception admissions during the period of Rotashie

47 the effect of Rotashield vaccination use on intussusception admissions in ten US states.

48 otashield dose), we estimated an increase in intussusception admissions of 1% (one excess admission)

49 re CD; and a mostly modest increased risk of intussusception after a diagnosis of CD.

50 tatistically significantly increased risk of intussusception after CD diagnosis (hazard ratio=1.95; 9

51 e possibility of a small increase in risk of intussusception after monovalent rotavirus vaccination.

52 7, 1999, after nine cases of infants who had intussusception after receiving the tetravalent rhesus-h

53 work was motivated by the documented risk of intussusception after RotaShield vaccination (Wyeth-Lede

54 ort study in a capture-recapture analysis of intussusception after rotavirus vaccination (RV).

55 new monovalent rotavirus vaccine (RV1) with intussusception after routine immunization of infants in

56 Cases of intussusception after RV were selected from the common t

57 The attributable risk of intussusception after the administration of two doses of

58 There was also an increase in the risk of intussusception after the second dose of the vaccine, bu

59 periods examined, the relative incidence of intussusception after vaccination was unchanged for 18,

60 Unexpected reports of intussusception after vaccination with the live tetraval

61 studies have identified an increased risk of intussusception after vaccination with the second-genera

62 served a significant increase in the rate of intussusception after vaccination, a risk that must be w

63 ing receipt of OPV during the month prior to intussusception among 119 cases and 589 controls matched

64 ntial analyses, we then compared the risk of intussusception among children receiving monovalent rota

65 the potential association between RRV-TV and intussusception among infants at least 1 but less than 1

66 We sought to determine the rate of intussusception among infants managed only with short-st

67 Hospital admission for intussusception among infants younger than 365 days of a

68 ociation between vaccination with RRV-TV and intussusception among otherwise healthy infants supports

69 ssibly cause a small increase in the risk of intussusception; an estimated 1-3 US infants out of 100

70 Data were analyzed for 429 infants with intussusception and 1763 matched controls in a case-cont

71 The relation between the risk of intussusception and age at the time of receipt of the fi

72 udies suggest a positive association between intussusception and celiac disease (CD).

73 they assume high vaccine-associated risk of intussusception and do not account for potential herd im

74 (72%) cases were associated with small bowel intussusception and five (28%) were not.

75 We found no association between intussusception and future CD; and a mostly modest incre

76 , surgical reduction, or hospitalization for intussusception and had been enrolled in Medicaid for at

77 RECENT FINDINGS: Intussusception and intestinal malrotation are potential

78 raise their awareness of imaging findings in intussusception and keep in their mind coexistent troubl

79 resence or absence of lymph nodes inside the intussusception and mesentery were noted.

80 ted that it is well tolerated with regard to intussusception and other adverse events and is efficaci

81 avirus vaccine efficacy data, global natural intussusception and regional rotavirus vaccine-related r

82 Loop remodeling occurs also by intussusception and results in the formation of compound

83 idence intervals for the association between intussusception and RV5 by comparing the rates of intuss

84 The diameters of the intussusception and the inner fat core, the outer bowel

85 s were reviewed to confirm the occurrence of intussusception and the status with respect to rotavirus

86 Potential cases of intussusception and vaccine exposures from 2004 through

87 s US, but also showed additional concomitant intussusceptions and inflamed appendix.

88 ckness was greater than 1.0 in all ileocolic intussusceptions and was less than 1.0 in all small-bowe

89 Revision, Clinical Modification code 560.0 (intussusception) and procedure codes and by review of me

90 , small bowel obstruction, internal hernias, intussusception, and recurrent weight gain.

91 f intussusception, the signs and symptoms of intussusception, and the need for prompt care.

92 described with reference to: the site of the intussusception, and the triggering lesion (either idiop

93 the rate of lipopolysaccharide (LPS)-induced intussusception, and this enhancement was replication de

94 ents 1% of all bowel obstructions, 5% of all intussusceptions, and 0.003%-0.02% of all hospital admis

95 Twenty-nine patients had enteroenteric intussusceptions, and four had intussusceptions involvin

96 unevaluable because of death at 3 weeks from intussusception; and 4 showed persisting mixed chimerism

97 ons of these findings on the pathogenesis of intussusception are discussed.

98 Early and subacute cases of intussusception are now ordinarily successfully reduced

99 The diagnosis and treatment of adult intussusception are surgical.

100 Intussusceptions are also postulated to result from alte

101 , as almost half of both colonic and enteric intussusceptions are associated with malignancy.

102 ion is a rare phenomenon, multiple transient intussusceptions are even more uncommon.

103 appendicitis accompanying multiple transient intussusceptions are much more uncommon.

104 = 90 days old accounted for 80% of cases of intussusception associated with a first dose but had rec

105 There was no significantly elevated risk of intussusception associated with receipt of OPV; 9.2% (11

106 at least significantly decrease the risk of intussusception associated with rotavirus vaccination.

107 inistered; this implies an increased risk of intussusception associated with RRV-TV at all ages studi

108 statistically significant increased risk of intussusception associated with RRV-TV for the exposure

109 We found that the incidence of intussusception associated with the first dose of vaccin

110 uted disproportionately to the occurrence of intussusception associated with the use of RotaShield.

111 Prior to identification of the intussusception association (January 1, 1987-July 14, 19

112 t patients with a postoperative diagnosis of intussusception at Mulago National Referral and Teaching

113 thin-walled blood vessels with sprouting or intussusception at the boundary of the ischemic lesion,

114 nd older with the postoperative diagnosis of intussusception at the Massachusetts General Hospital du

115 ion with RRV-TV, we estimated that 1 case of intussusception attributable to the vaccine would occur

116 cessary in a high percentage of infants with intussusception, but does not reduce the incidence of in

117 underestimate the true incidence of level 1 intussusception by >40%.

118 ciation between oral polio vaccine (OPV) and intussusception by linking Scottish vaccination and hosp

119 We assessed the incidence of intussusception by month of life among children <1 year

120 d the age-stratified background incidence of intussusception by use of Healthcare Cost and Utilizatio

121 Because intussusception can be associated with enlargement of gu

122 n upper limit for the attributable risk of 1 intussusception case per 65,287 RV5 dose-1 recipients.

123 red during the study period, with 8 observed intussusception cases (7.11 expected), for a nonsignific

124 m policy considerations, we estimated excess intussusception cases and mortality potentially caused b

125 Analysis was carried out for 466 intussusception cases occurring in 1987-1999 for which l

126 Intussusception cases occurring in infants were identifi

127 se of vaccination far exceeded the number of intussusception cases that may have been associated with

128 e two doses combined, the expected number of intussusception cases was 0.72, resulting in a significa

129 owing all RV5 doses, we observed 21 cases of intussusception compared with 20.9 expected cases (SIR,

130 were given OPV 0-28 days prior to the case's intussusception date (odds ratio=1.1, 95% confidence int

131 Medicaid for at least 1 month prior to their intussusception date.

132 2,000-281,500) while potentially causing 547 intussusception deaths (237-1,160).

133 3,300-217,700) while causing potentially 253 intussusception deaths (76-689).

134 rotavirus deaths prevented and the number of intussusception deaths caused by vaccination when admini

135 3,700) and cause an additional 294 (161-471) intussusception deaths, for an incremental benefit-risk

136 mber the potential excess vaccine-associated intussusception deaths.

137 and clinical records of all patients with an intussusception demonstrated on CT or MR images from Jan

138 Less than one-third of adult intussusceptions demonstrated at CT or MR imaging were c

139 Thirty-three patients had one or more intussusceptions demonstrated on CT (n = 30) or MR (n =

140 n distinguishing the majority of small-bowel intussusceptions detected at CT that are self-limiting f

141 Rotavirus-induced intussusceptions did not have observable lymphoid lead p

142 Excess admissions for intussusception during the period of Rotashield availabi

143 evidence for an association between OPV and intussusception, even when each dose is considered separ

144 ation at ages 2, 4, and 6 months projected 1 intussusception event/11,000-16,000 vaccine recipients;

145 beginning in the neonatal period projected 1 intussusception event/38,000-59,000 vaccine recipients.

146 s, in comparing rotavirus disease averted to intussusception events caused, the hospitalization ratio

147 n has been limited to young infants owing to intussusception events noted with a prior rotavirus vacc

148 ates, because of a temporal association with intussusception events that occurred in vaccinated infan

149 outh America that reported a total of 44,454 intussusception events.

150 Of 156 infants with intussusception fulfilling Brighton level 1 criteria, 81

151 Children with ileocolic intussusception had more severe clinical symptoms and si

152 esus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new va

153 oscopy) in Peutz-Jeghers Syndrome to prevent intussusception have been newly described.

154 ined age-specific trends in population-level intussusception hospitalization rates before (2000-2005)

155 evious rotavirus vaccine, RotaShield, caused intussusception in 1 of every 10,000 recipients, we asse

156 There were 200 cases of intussusception in 174 patients (126 boys, 48 girls; mea

157 rol analysis as well as for 432 infants with intussusception in a case-series analysis.

158 confidence interval: 1,551, 2,025) cases of intussusception in a fully vaccinated, national cohort o

159 Management of intussusception in a pediatric center shows changing pat

160 RV1 was associated with a short-term risk of intussusception in approximately 1 of every 51,000 to 68

161 t of intussusception, we reviewed studies of intussusception in children <18 years of age published s

162 susception and RV5 by comparing the rates of intussusception in infants who had received RV5 with the

163 fants who had received RV5 with the rates of intussusception in infants who received other recommende

164 rotavirus vaccines were not associated with intussusception in large prelicensure trials.

165 ere not associated with an increased risk of intussusception in large trials before licensure, recent

166 A combined annual excess of 96 cases of intussusception in Mexico (approximately 1 per 51,000 in

167 A radiographic modality was used to diagnose intussusception in over 95% of the cases in all regions

168 a causal link between rotavirus vaccines and intussusception in some settings.

169 The relative risks of intussusception in the periods 3-7 and 8-14 days after R

170 We recorded six cases of intussusception in the vaccine group and two in the plac

171 ors examined the association between OPV and intussusception in the Washington State Medicaid populat

172 nical data for children given a diagnosis of intussusception in the years 2007 through 2011 were eval

173 t to conduct the first review study of adult intussusception in Uganda.

174 us vaccines showed almost identical rates of intussusception in vaccine and placebo recipients.

175 11 (4%), jejunal hematomas in five (2%), and intussusceptions in four (1%).

176 Enteric intussusceptions in the nonneoplastic group were shorter

177 cribed; four died between 7 to 106 days with intussusception, infection, or GVHD, and five became lon

178 hospital (<365 days old) with any mention of intussusception (International Classification of Disease

179 lastic lead point, including all four of the intussusceptions involving the colon (benign mass, n = 3

180 enteroenteric intussusceptions, and four had intussusceptions involving the colon.

181 Intussusception is a different entity in adults than it

182 Intussusception is a form of intestinal obstruction in w

183 Adult intussusception is a rare clinical condition worldwide.

184 Adult intussusception is a rare phenomenon, acute appendicitis

185 Adult intussusception is a rare phenomenon, multiple transient

186 LPS-induced intussusception is associated with the induction of infl

187 The management of both pediatric and adult intussusception is considered.

188 ted heterotopic pancreas as a cause of bowel intussusception is extremely rare.

189 ding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months

190 ever, to address the hypothesis that risk of intussusception is related to receipt of a particular do

191 Adult intussusception is uncommon in the Uganda, though probab

192 Estimates of the risk of intussusception (IS) associated with currently licensed

193 Intussusception (IS) is a form of acute intestinal obstr

194 The objectives were to review adult intussusception, its diagnosis, and its treatment.

195 Seventeen patients had an intussusception length greater than 3.5 cm, as measured

196 Intussusception length is the main factor in distinguish

197 All 20 patients with an intussusception length of 3.5 cm or less, as measured by

198 tepwise, logistic regression analysis showed intussusception length was the only variable that was in

199 The presence of an inner fatty core in the intussusception, lesion diameter, wall thickness, the ra

200 This review of the intussusception literature from the past decade provides

201 five surgically confirmed masses (carcinoid, intussusception, lymphangioma) were identified, but two

202 ortality by week of age from a recent study, intussusception mortality based on a literature review,

203 ccines with regard to the associated risk of intussusception must be demonstrated as well.

204 evious rotavirus vaccine was associated with intussusception, new rotavirus vaccines are monitored po

205 um schedule to avoid or significantly reduce intussusception, now reported to be associated in intern

206 a) and used worldwide spontaneous reports of intussusception occurring after Rotarix vaccination (Gla

207 Intussusception occurring in the 1- to 7-day and 1- to 3

208 helial polarity and proliferation leading to intussusception of endothelial cells and extensive remod

209 gation provide support for the idea that the intussusception of newly secreted pectin contributes to

210 There were 5 deaths due to pneumonia (n=1), intussusception of the graft (n=1), cardiorespiratory ar

211 yses regarding the dependence of the risk of intussusception on age at first dose.

212 and quiting imaging studies after finding an intussusception on ultrasound, may lead diagnostic error

213 1.42 cm (range, 0.8-3.0 cm) for small-bowel intussusception (P < .0001).

214 us 0.1 cm (range, 0-0.75 cm) for small-bowel intussusception (P < .0001).

215 ons and was less than 1.0 in all small-bowel intussusceptions (P < .0001).

216 ersus in eight (14.0%) of the 57 small-bowel intussusceptions (P < .0001).

217 l evaluation of patients suspected of having intussusception, particularly when the supine view is di

218 The number of excess cases of intussusception per 100,000 recipients of the first dose

219 ely 1.5 (95% CI, 0.2 to 3.2) excess cases of intussusception per 100,000 recipients of the first dose

220 to identify an array of diseases, including intussusception, pyloric stenosis and appendicitis.

221 Six possible risk periods for intussusception, ranging from 3 days after vaccination t

222 The mean annual intussusception rate for the hospitals' catchment counti

223 Accurate background intussusception rates are needed to determine whether th

224 Intussusception rates based solely on inpatient discharg

225 the induction of inflammatory mediators, and intussusception rates can be modified by inflammatory an

226 us vaccine introduction, a small increase in intussusception rates was seen among US infants aged 8-1

227 Previously, intussusception rates were obtained from inpatient disch

228 fects of subsequent LPS treatment to enhance intussusception rates.

229 Treatment did not involve intussusception reduction in 14 patients (37.8%).

230 traperitoneal hemorrhage; the second died of intussusception-related bowel necrosis 10 days after TEP

231 Adult intussusception represents 1% of all bowel obstructions,

232 d internationally, to further quantitate the intussusception risk following each vaccine.

233 Although US data have not documented an intussusception risk with current rotavirus vaccines, in

234 s of vaccine efficacy and vaccine-associated intussusception risk.

235 Ambulatory or nonhospital management of intussusception subjects the infant to the risk of a sig

236 this review relates to the heterogeneity in intussusception surveillance across different regions.

237 ion that should facilitate implementation of intussusception surveillance for monitoring the postlice

238 esection of the ureteral orifice (pluck) and intussusception techniques should be approached with cau

239 An intussusception that is shorter than 3.5 cm is likely to

240 t was self-limiting, and six patients had an intussusception that required surgery.

241 abdominal CT not only confirmed the enteric intussusception that was demonstrated on previos US, but

242 Eleven patients had an intussusception that was self-limiting, and six patients

243 oviders should be aware of the small risk of intussusception, the signs and symptoms of intussuscepti

244 To minimize potential risk of intussusception, the World Health Organization (WHO) rec

245 ants are relatively refractory to developing intussusception, thereby avoiding the age period when na

246 isting with multiple spontaneously resolving intussusceptions, to the literature.

247 000 each in order to address questions about intussusception triggered by a third earlier vaccine.

248 ere seen in 128 (89.5%) of the 143 ileocolic intussusceptions versus in eight (14.0%) of the 57 small

249 rrent period and with the expected number of intussusception visits based on background rates assesse

250 .12%) individuals with CD had a diagnosis of intussusception vs. 143 (0.10%) reference individuals, s

251 CD in patients with at least two records of intussusception was 0.40 (95% CI=0.06-2.99).In contrast,

252 The mean incidence of intussusception was 74 per 100,000 (range: 9-328) among

253 1 per 68,000 infants) and of 5 deaths due to intussusception was attributable to RV1.

254 Intussusception was correctly excluded with the KUB view

255 Intussusception was correctly identified with KUB view a

256 Moreover, the frequency of intussusception was increased when the compound mutant m

257 Each infant with intussusception was matched according to age with four h

258 .10%) reference individuals, suggesting that intussusception was not a risk factor for later CD (OR=1

259 4 to 34 weeks who received RV5, the risk of intussusception was not increased compared with infants

260 Intussusception was present in 58 of 304 studies (19%).

261 ccination was associated with 1,400 cases of intussusception, was $36 (95% confidence interval: $28,

262 background rates and clinical management of intussusception, we reviewed studies of intussusception

263 dies and the ability to visualize or exclude intussusception were calculated to determine sensitivity

264 ratios (ORs) for future CD in patients with intussusception were estimated using conditional logisti

265 Thirty-seven cases of adult small-bowel intussusception were identified by a retrospective compu

266 Cases of intussusception were identified from nationwide inpatien

267 Infants with intussusception were identified through active surveilla

268 ccine was withdrawn when reports of cases of intussusception were linked to recent vaccination.

269 Ninety-three percent of the intussusceptions were associated with a pathologic lesio

270 Low-grade intussusceptions were more prevalent with the liquid med

271 drawn in 1999 due to a rare association with intussusception, which occurred disproportionately in in

272 vaccines are introduced globally, monitoring intussusception will be crucial for ensuring safety of t

273 nsure identification of an increased risk of intussusception with rotavirus vaccine, the 14 Latin Ame

274 statistically significant increased risk of intussusception with RV5 for either comparison group fol

275 after studies observed an increased risk of intussusception within 2 weeks after immunization.

276 The relative risk of chart-confirmed intussusception within 7 days after monovalent rotavirus

277 We reviewed medical records and visits for intussusception within 7 days after monovalent rotavirus

278 We identified 6 cases of intussusception within 7 days after the administration o

279 1-3 US infants out of 100 000 might develop intussusception within 7 days of getting their first dos

280 Surgical resection of the intussusception without reduction is the preferred treat

281 126-293) and 10 deaths (90% CI, 6-17) due to intussusception, yielding benefit-risk ratios for hospit